



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Fax Cover Sheet

Date: 10 May 2010

To: S. Mosoff	From: Sandra Saucier
Application/Control Number: 10/511,700	Art Unit: 1651
Fax No.: 212-808-0844	Phone No.: (571) 272-0922
Voice No.: 212-808-0700	Return Fax No.:
Re:	CC:
<input checked="" type="checkbox"/> Urgent	<input type="checkbox"/> For Review
<input type="checkbox"/> For Comment	<input checked="" type="checkbox"/> For Reply
	<input type="checkbox"/> Per Your Request

Comments:

Upon acceptance of the proposed examiner's amendment, claims 47-57, 59, 62 would be allowable.

Number of pages __ including this page

STATEMENT OF CONFIDENTIALITY

This facsimile transmission is an Official U.S. Government document which may contain information which is privileged and confidential. It is intended only for use of the recipient named above. If you are not the intended recipient, any dissemination, distribution or copying of this document is strictly prohibited. If this document is received in error, you are requested to immediately notify the sender at the above indicated telephone number and return the entire document in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PROPOSED EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claims 10, 14-24, 58, 60, 61, 63-68 have been cancelled.

47. A method for accelerating angiogenesis in a patient comprising: topically administering to the patient, at a site where angiogenesis acceleration is desired, a fibrin matrix made by the process of forming the fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable carrier, wherein the fibrinogen has a high molecular weight content (HMW) of at least 80% (w/w) of the total fibrinogen amount.

Claim 49, line 2, "a" has been changed to ---the---.

Claim 50, line 2, "a" has been changed to ---the---.

Claim 51, line 2, the first "a" has been changed to ---the---.

Claim 59, line 2, "a" has been changed to ---the---.

Claim 62, line 2, the second "a" has been changed to ---the---.

54. A method for decelerating angiogenesis in a patient comprising: topically administering to the patient, at a site where angiogenesis deceleration is desired, a fibrin matrix made by the process of forming the fibrin matrix from a composition comprising fibrinogen and a pharmaceutically acceptable

carreier, wherein the fibrinogen has a low molecular weight content (LMW) of at least 40% (w/w) of the total fibrinogen amount.

Claim 62, line 1, "58" has been changed to ---54---.